One of the reasons for the lengthy tuberculosis (TB) treatment is the difficulty to treat the
nonmultiplying mycobacterial subpopulation. In order to assess the ability of (new) TB drugs …

Sir, A key problem in tuberculosis control is the persistence of Mycobacterium tuberculosis
despite prolonged chemotherapy: treatment for 6–12 months is required to cure acute …

Objectives Mycobacterium tuberculosis can exist in different states in vitro, which can be
denoted as fast multiplying, slow multiplying and non-multiplying. Characterizing the natural …

Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which …

Tuberculosis remains a threat to global health and recent attempts to shorten therapy have
not succeeded mainly due to cases of clinical relapse. This has focussed attention on the …

Nonreplicating or dormant cells of Mycobacterium tuberculosis constitute a challenge to
tuberculosis (TB) therapy because of their tolerance or phenotypic resistance to most drugs …

The pathology of tuberculosis in humans starts with an initial Ghon focus in the lungs
followed by transmission of bacilli though the blood and lymph to other regions in the lungs …

Dormancy models for Mycobacterium tuberculosis play important roles in understanding
various aspects of tuberculosis pathogenesis and in the testing of novel therapeutic …

Biomarkers are quantifiable characteristics of biological processes. In Mycobacterium
tuberculosis, common biomarkers used in clinical drug development are colony forming unit …

Mycobacterium tuberculosis 18b, a streptomycin (STR)-dependent mutant that enters a
viable but nonreplicating state in the absence of STR, has been developed as a simple …